Urgent Phase I/II Clinical Trials to Repurpose Existing Therapeutic Agents to Treat COVID-19 Sequelae (U01 Clinical Trial Required)

US Dept. of Health & Human Services: National Institutes of Health (NIH)

Suggest an update

Deadline: Jan 23, 2021

Grant amount: Up to US $9,000,000

Fields of work: Respiratory Diseases & Systems Infectious & Parasitic Diseases

Applicant type: Organizations

Funding uses: Clinical Biomedical

Location of project: United States

Location of residency: United States

View website    Save

Overview:

NOTE: Applications will be accepted on a rolling basis, beginning on August 6, 2020. All applications are due by 5:00 PM local time of applicant organization. 

The purpose of this urgent funding opportunity announcement is to invite applications to repurpose existing therapeutic agents to treat Coronavirus Disease 2019 (COVID-19) sequelae and associated complications that result from Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infections. The therapeutic agent must have already completed at least a Phase I clinical trial for a different indication, and not require additional regulatory studies for the new indication prior to starting a clinical trial.

We've imported the main document for this grant to give you an overview. You can learn more about this opportunity by visiting the funder's website.

This page was last reviewed September 14, 2020 and last updated September 14, 2020